Last Updated : September 14, 2023
The class of sodium-glucose cotransporter-2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes mellitus. Evidence informing the place in therapy of SGLT2 inhibitors has matured since CADTH last assessed this drug class. Public drug programs have requested a review to assess the optimal use of SGLT2 inhibitors after a trial of metformin.
This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects in Progress.
|Posting of Draft Scope for stakeholder feedback||September 14|
|End of feedback period||September 28|